XML 50 R17.htm IDEA: XBRL DOCUMENT
v3.19.3

Shareholders' Equity | 9 Months Ended
--- | ---
Sep. 30, 2019
Stockholders' Equity Note [Abstract] |
Shareholders' Equity | 10. SHAREHOLDERS’ EQUITY At-the-Market Offering In January 2018, the Company entered into a common stock sales agreement with a financial institution pursuant to which the Company could offer and sell, through the sales agent, common stock representing an aggregate offering price of up to $2.5 million through an at-the-market continuous offering program. During the nine months ended September 30, 2018, the Company issued 1,288,537 shares of common stock at an average price of $1.41 for total net proceeds before offering expenses of approximately $1,817 thousand. Offering expenses, including broker fees and legal costs related to the at-the-market offering totaled $151 thousand. In January 2019, the Company terminated the at-the-market offering. Warrants In December 2016, the Company completed a registered direct offering of 1,000,000 shares of common stock at a net gross price of $1.50 per share. Concurrently, the investors received warrants to purchase 1,000,000 shares of common stock of the Company at an exercise price of $2.05 per share, subject to adjustment, for a period of five years from closing. The total net proceeds received by the Company were approximately $1.32 million. The fair value of the warrants upon issuance was $1.24 million, with the remaining $80 thousand being attributed to common stock. The warrants have been classified as liabilities due to features in the warrant agreement that give the warrant holder an option to require the Company to redeem the warrant at a calculated fair value in the event of a “Fundamental Transaction,” as defined in the warrant agreement. The fair value of the warrants was $206 thousand and $425 thousand at September 30, 2019 and December 31, 2018, respectively Pursuant to the warrant agreement, the warrant exercise price was reduced from $2.05 to $1.13 per share as a result of common stock issuances made during the three-month period ended March 31, 2018. Stock Options From time to time, the Company may grant stock options under its incentive plan covering shares of common stock to employees of the Company. Stock options, when exercised, are settled through the payment of the exercise price in exchange for new shares of stock underlying the option. These awards typically expire ten years from the grant date. For both the nine months ended September 30, 2019 and 2018, total stock-based compensation expense related to stock options was $39 thousand. As of September 30, 2019, there was $6 thousand of unrecognized expense related to unvested stock options, which will be recognized as stock-based compensation expense through November 2019. For the nine months ended September 30, 2019, no stock options were granted, exercised or expired. As the result of an employee termination during the period, 5,000 unvested stock options were forfeited. For the nine months ended September 30, 2018, no stock options were granted, exercised or forfeited, however, 69,225 stock options expired during the period. Presented below is information about stock options outstanding and exercisable as of September 30, 2019 and December 31, 2018:
|  | September 30, 2019 |  |  | December 31, 2018 |
|  | Shares |  |  | Price (1) |  |  | Shares |  |  | Price (1) |
Stock options outstanding |  |  | 315,462 |  |  | $ | 6.61 |  |  |  | 320,462 |  |  | $ | 6.52 |
Stock options exercisable |  |  | 265,462 |  |  | $ | 7.63 |  |  |  | 265,462 |  |  | $ | 7.63 |
| (1) | Represents the weighted average price.
The following table summarizes information for stock options outstanding and for stock options exercisable at September 30, 2019:
Options Outstanding |  |  | Options Exercisable |
|  |  | Exercise Price |  |  |  |  |  |  |  |  |  |
Number of Shares |  |  | Low |  |  | High |  |  | Weighted Average |  |  | Remaining Contractual Term (years) |  |  | Number of Shares |  |  | Weighted Average Exercise Price |
| 165,000 |  |  | $ | 0.72 |  |  | $ | 1.16 |  |  | $ | 1.00 |  |  |  | 8.0 |  |  |  | 115,000 |  |  | $ | 0.93 |
| 106,290 |  |  |  | 9.00 |  |  |  | 12.48 |  |  |  | 10.62 |  |  |  | 4.6 |  |  |  | 106,290 |  |  |  | 10.62 |
| 29,171 |  |  |  | 13.92 |  |  |  | 17.10 |  |  |  | 14.74 |  |  |  | 2.7 |  |  |  | 29,171 |  |  |  | 14.74 |
| 15,001 |  |  |  | 22.62 |  |  |  | 30.24 |  |  |  | 24.03 |  |  |  | 3.8 |  |  |  | 15,001 |  |  |  | 24.03 |
| 315,462 |  |  | $ | 0.72 |  |  | $ | 30.24 |  |  | $ | 6.61 |  |  |  | 6.2 |  |  |  | 265,462 |  |  | $ | 7.63 |
In May 2018, the Company recognized stock-based compensation expense of $583 thousand related to 485,168 unrestricted shares of common stock granted to employees. As of September 30, 2019, there was no unrecognized expense related to common stock grants.

X
- Definition The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP). + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -URI http://asc.fasb.org/topic&trid=2208762 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -URI http://asc.fasb.org/topic&trid=2228938 + Details
Name: | us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_StockholdersEquityNoteAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration